Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, has announced plans to advance its investigational drugs SION-719 and SION-451 to the next stage of clinical development. SION-719 will be evaluated in a Phase 2a proof-of-concept trial as an add-on to the standard of care in cystic fibrosis patients. Additionally, SION-451 will undergo a Phase 1 trial in healthy volunteers, testing dual combinations with SION-2222 and SION-109. Both trials are set to commence in the second half of 2025, with data expected by mid-2026. Preclinical data demonstrating the potential of these dual combinations to achieve full CFTR correction in CF models were presented at the 48th European Cystic Fibrosis Conference.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.